Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 2/3 1Phase 1/2 1

Status

Terminated 2Recruiting 2Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Plasma cell 44Lymphoid 6Other hematologic neoplasm 5Other 1Gastrointestinal 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Neoplasms 1Natural Killer/T-cell Lymphoma 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia, Myeloid, Acute 1Immunoproliferative Disorders 1

Interventions

Cyclophosphamide 342Rituximab 304Vincristine 157Doxorubicin 154venetoclax 153fludarabine 153Specimen Handling 152Prednisone 150Biopsy 122Magnetic Resonance Spectroscopy 117obinutuzumab 116Lenalidomide 109Dexamethasone 104Cytarabine 97ibrutinib 95Etoposide 92fludarabine phosphate 87Methotrexate 84acalabrutinib 78Bendamustine Hydrochloride 72zanubrutinib 71blinatumomab 63pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45glofitamab 44Calcium Dobesilate 44Mercaptopurine 43prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
isatuximab × Lymphoid × 1 year × Clear all
NCT04763616 2026-04-27

ICING

Samsung Medical Center

Phase 2 Completed
37 enrolled
Lymphoid

Natural Killer/T-cell Lymphoma

NCT05804032 2026-02-18

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

University of Heidelberg Medical Center

Phase 3 Completed
514 enrolled
LymphoidPlasma cell

Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Paraproteinemias

NCT06860269 2026-02-10

GRAALL-2024

Assistance Publique - Hôpitaux de Paris

Phase 2/3 Recruiting
1,200 enrolled
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06648889 2026-01-15

Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Goethe University

Phase 2 Recruiting
40 enrolled
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03769181 2025-09-23

A Study of Isatuximab-based Therapy in Participants With Lymphoma

Sanofi

Phase 1/2 Terminated
58 enrolled 37 charts
Lymphoid

Lymphoma

NCT03860844 2025-09-09

ISAKIDS

Sanofi

Phase 2 Terminated
67 enrolled 25 charts
LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡